Sci-Tech Legal

Go to Article
Excerpt from www.aol.com

Hunter Biden is agreeing to drop a civil lawsuit against Rudy Giuliani and Giuliani’s former lawyer Robert Costello, according to a court filing Thursday.

The president’s son last year formally accused Giuliani and Costello of violating computer fraud and data access laws, alleging they manipulated data from his “devices or storage platforms.”

Attorneys for all three parties filed the agreement, which stipulates that Biden agrees to drop the lawsuit and that each man will pay his own legal fees.

The lawsuit initially sought more than $75,000 in damages, as well as attorneys’ fees and other penalties.

“As Giuliani is in bankruptcy and agreed to have the case waiting for when he is done, it made no sense to continue it in a non-bankruptcy court until that happens,” a person familiar with the filing told NBC News on Thursday.

Go to Article
Excerpt from www.forbes.com

Reducing prescription drug prices has long been a goal of Democrats in Congress and the White House. But in a strange twist, a group of Senate Democrats—along with one Republican—has backed a bill that would increase drug prices by preventing people from challenging weak or invalid patents.

 

Go to Article
Excerpt from news.bloomberglaw.com

Twenty-seven states and three tech trade groups urged the Federal Circuit not to scrap Idaho’s “anti-patent troll” law in response to an unprecedented challenge to its constitutionality.

Idaho’s law barring the bad-faith assertion of patents in court—and particularly a bond requirement it imposes on non-practicing entities—is before the court in appeals filed by Longhorn IP LLC and an affiliate, Katana Silicon Technologies LLC.

Go to Article
Excerpt from www.thedefensepost.com

In an election year, bipartisan issues are hard to come by. However, protecting American innovation from foreign threats, like those posed by China, is a cause policymakers from all political parties should align behind.

 

Many of China’s damaging practices — like stealing Americans’ personal information and providing domestic firms massive subsidies to dominate global markets — are becoming more obvious.

But others are sleeper issues that need more attention to ensure we prevent serious harm to our technology future.

Go to Article
Excerpt from www.fiercepharma.com

Pfizer unit wins $107.5M verdict in cancer-drug patent case against AstraZeneca  FiercePharma